Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most thyroid-related safety concepts (immune-mediated thyroid disorders, hypothyroidism/hyperthyroidism/thyroiditis, need for hormone replacement/medical management, and general need to monitor thyroid function) are supported by the provided label excerpt. However, multiple statements about specific symptom lists and specific monitoring practices (exact tests like TSH/free T4; frequency; clinician ordering) and treatment-management details (how to monitor transitions; general persistence wording) are not directly supported in the provided labeling text.
Category Scores
Accurate Statements
Keytruda can cause immune-mediated thyroid disorders (including thyroiditis) and can cause hypothyroidism and hyperthyroidism.
WARNINGS AND PRECAUTIONS 5.1, section "Thyroid Disorders": "KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism."
Thyroiditis can occur with KEYTRUDA.
WARNINGS AND PRECAUTIONS 5.1, "Thyroid Disorders": "Thyroiditis occurred in 0.6% (16/2799)..."
Hypothyroidism can occur with KEYTRUDA, and most patients required long-term thyroid hormone replacement.
WARNINGS AND PRECAUTIONS 5.1, "Thyroid Disorders": "Hypothyroidism occurred in 8%... The majority of patients with hypothyroidism required long-term thyroid hormone replacement."
Hyperthyroidism can occur with KEYTRUDA.
WARNINGS AND PRECAUTIONS 5.1, "Thyroid Disorders": "Hyperthyroidism occurred in 3.4%..."
Management for hypothyroidism is hormone replacement; management for hyperthyroidism is medical management as clinically indicated.
WARNINGS AND PRECAUTIONS 5.1, "Thyroid Disorders": "Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated."
Thyroid disorders are part of immune-mediated adverse reactions that may occur during treatment and can also occur after discontinuation of PD-1/PD-L1 blocking antibodies.
WARNINGS AND PRECAUTIONS 5.1 (intro): "Immune-mediated adverse reactions can occur at any time after starting treatment... [and] can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies."
Unsupported Statements
Hypothyroid symptoms that can be seen with Keytruda thyroid changes include fatigue.
The provided label excerpt does not list specific hypothyroid symptom examples such as fatigue.
Hypothyroid symptoms that can be seen with Keytruda thyroid changes include weight gain.
Specific symptom lists (e.g., weight gain) are not provided in the supplied label excerpt.
Hypothyroid symptoms that can be seen with Keytruda thyroid changes include feeling cold.
Specific symptom lists are not provided in the supplied label excerpt.
Hypothyroid symptoms that can be seen with Keytruda thyroid changes include constipation.
Specific symptom lists are not provided in the supplied label excerpt.
Hypothyroid symptoms that can be seen with Keytruda thyroid changes include slower heart rate.
Specific symptom lists are not provided in the supplied label excerpt.
Hypothyroid symptoms that can be seen with Keytruda thyroid changes include dry skin.
Specific symptom lists are not provided in the supplied label excerpt.
Hyperthyroid symptoms that can be seen with Keytruda thyroid changes include anxiety or restlessness.
Specific symptom lists are not provided in the supplied label excerpt.
Hyperthyroid symptoms that can be seen with Keytruda thyroid changes include weight loss.
Specific symptom lists are not provided in the supplied label excerpt.
Hyperthyroid symptoms that can be seen with Keytruda thyroid changes include heat intolerance.
Specific symptom lists are not provided in the supplied label excerpt.
Hyperthyroid symptoms that can be seen with Keytruda thyroid changes include sweating.
Specific symptom lists are not provided in the supplied label excerpt.
Hyperthyroid symptoms that can be seen with Keytruda thyroid changes include tremor.
Specific symptom lists are not provided in the supplied label excerpt.
Hyperthyroid symptoms that can be seen with Keytruda thyroid changes include faster heart rate.
Specific symptom lists are not provided in the supplied label excerpt.
Hyperthyroid symptoms that can be seen with Keytruda thyroid changes include heart palpitations.
Specific symptom lists are not provided in the supplied label excerpt.
Clinicians generally check thyroid blood tests (especially TSH and free T4) when thyroid abnormalities are found during Keytruda treatment.
The excerpt states to evaluate thyroid function but does not specify TSH or free T4 or how/when tests are generally checked.
If hyperthyroidism occurs with Keytruda, management may involve symptom control and close monitoring.
The excerpt says "institute medical management of hyperthyroidism as clinically indicated" but does not specify symptom control and close monitoring.
If hyperthyroidism occurs with Keytruda, treatment adjustments may be made as the thyroid condition evolves.
Dose modification/discontinuation principles are severity-based, but the excerpt does not support this general statement about adjustments as the thyroid condition evolves.
If thyroiditis is suspected with Keytruda, treatment is guided by labs and symptoms.
The excerpt states withholding/discontinuing depending on severity and hormone replacement/medical management as clinically indicated, but it does not specify that thyroiditis treatment is guided by labs and symptoms.
If thyroiditis is suspected with Keytruda, clinicians monitor for transitions between hyperthyroid and hypothyroid phases.
The excerpt states "Hypothyroidism can follow hyperthyroidism" but does not state that clinicians monitor for transitions specifically for suspected thyroiditis.
Thyroid function monitoring is standard with PD-1 inhibitors like pembrolizumab because abnormalities may be detectable even before symptoms become obvious.
The excerpt mentions evaluating thyroid function at baseline and periodically during treatment, but does not support the phrasing that monitoring is 'standard' for PD-1 inhibitors broadly or that abnormalities may be detectable before symptoms.
If symptoms appear during Keytruda treatment, the oncology team typically orders thyroid labs.
The excerpt advises monitoring patients closely for symptoms and evaluating thyroid function, but does not support that clinicians 'typically' order thyroid labs upon symptom appearance.
The oncology team decides whether treatment changes are needed based on thyroid labs.
The excerpt provides general guidance to withhold/discontinue depending on severity and to evaluate thyroid function, but does not state treatment decisions are made based specifically on thyroid labs.
Immune-related endocrine effects can be longer-lasting than other side effects after Keytruda is stopped.
The excerpt does not compare duration across side effects; it only supports that immune-mediated adverse reactions can occur after discontinuation and that hypothyroidism often requires long-term replacement.
Hypothyroidism may persist after stopping Keytruda.
The excerpt supports that hypothyroidism requires long-term thyroid hormone replacement (and that immune-mediated adverse reactions can manifest after discontinuation), but it does not explicitly state hypothyroidism 'may persist after stopping'.
Hypothyroidism may require ongoing thyroid hormone replacement after Keytruda is stopped.
The excerpt states "The majority of patients with hypothyroidism required long-term thyroid hormone replacement" but does not explicitly tie replacement continuation to stopping KEYTRUDA.
The persistence of hypothyroidism after Keytruda depends on the individual’s recovery and follow-up lab results.
No label support is provided for this dependence phrasing in the supplied excerpts.
With Keytruda, patients should promptly report symptoms that could signal thyroid dysfunction.
The excerpt instructs to monitor patients closely for symptoms/signs and to evaluate thyroid function, but it does not specifically instruct patients to promptly report thyroid dysfunction symptoms.
Symptoms that could signal Keytruda thyroid dysfunction include new or worsening fatigue/weight change/heat intolerance/tremor/palpitations/anxiety/restlessness/constipation/feeling unusually cold.
Specific symptom examples as indicators of thyroid dysfunction are not provided in the supplied label excerpt.
Contradictions
Important Omissions
For thyroid disorders, the label specifies withholding or permanently discontinuing KEYTRUDA depending on severity; the AI statements did not include this severity-based discontinuation/withholding instruction for thyroid disorders.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the core immune-mediated thyroid disorder warnings and general management concepts are supported, the response includes many detailed symptom lists and specific monitoring/ordering/treatment-adjustment claims that are not supported by the provided labeling excerpt. This could lead to inaccurate expectations about symptom specificity and clinical workflow; also, severity-based withholding/discontinuation guidance for thyroid disorders is omitted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple symptom-specific and practice-specific statements (e.g., TSH/free T4 emphasis, 'typical' ordering, transitions monitoring, symptom-based reporting guidance, and duration/persistence wording) are not directly supported by the supplied label text, and severity-based withholding/discontinuation for thyroid disorders was not included.
Suggested Improvement
Limit thyroid disorder content to what is explicitly supported in the excerpt: immune-mediated thyroid disorders (thyroiditis, hypothyroidism, hyperthyroidism), that hypothyroidism can follow hyperthyroidism, initiate hormone replacement for hypothyroidism or medical management for hyperthyroidism as clinically indicated, and withhold or permanently discontinue KEYTRUDA depending on severity; also use label-supported monitoring language (evaluate thyroid function at baseline and periodically).